SOX9 and non-small cell lung carcinoma: The TME in non-small cell lung cancer (NSCLC) is often hypoxic, hypoxia promote cancer cell stemness and invasion by promoting glycolysis via lactylation of SOX9 (6), and it increased PD-L1 to suppress T-cell activation and function, Metabolic intervention that alleviates hypoxia and reduces PD-L1 expression enhances lung cancer radio-immunotherapy (7).